查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1137021

結合型疫苗市場:各產品類型，疾病各適應症，各病原體類型，各患者類型，各地區- 規模，佔有率，展望，機會分析，2022年～2030年

Conjugate Vaccine Market, by Product Type, by Disease Indication, by Pathogen Type, by Patient Type, and by region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030
出版日期: | 出版商: Coherent Market Insights | 英文 186 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

市場動態

預計在預測期內，越來越多的肺炎患者將推動全球結合疫苗市場的增長。

本調查的主要特徵

  • 本報告提供以2021年為基準年的預測期間（2022-2030 年）之全球結合型疫苗市場的市場規模和復合年增長率（CAGR %）相關的詳細分析。
  • 並闡明不同部門市場的潛在收入機會，說明該市場具有魅力的投資主張矩陣。
  • 同時並提供市場推動因素和限制、機會、新產品發布或批准、市場趨勢、區域前景和主要參與者採用的競爭戰略等重要考察。
  • 並基於企業亮點，各類型投資組合、主要焦點、財務業績和市場策略等參數，介紹全球結合型疫苗市場的主要參與者之企業簡介。
  • 藉由該報告提供的洞察，將能幫助營銷人員和公司高管能夠就未來的產品發布、類型升級、市場擴張和營銷策略做出明智的決策。
  • 全球結合型疫苗市場報告配合該行業的各種利益相關者，包括投資者、供應商、產品製造商、分銷商、新進入者和金融分析師。
  • 利益相關者可以透過全球結合型疫苗市場用於分析的各種戰略矩陣來幫助他們更容易做下決策。

目錄

第1章 調查目的與前提條件

  • 調查目的
  • 前提條件
  • 簡稱的說明

第2章 市場展望

  • 報告內容
  • 市場定義和範圍
  • 摘要整理
    • 市場概述:各產品類型
    • 市場概述:疾病各適應症
    • 市場概述:各病原體類型
    • 市場概述:各患者類型
    • 市場概述:各地區
  • 連貫機遇地圖(COM)

第3章 市場動態，法規，及趨勢的分析

  • 市場動態
    • 促進因素
    • 阻礙因素
    • 市場機會
  • 影響分析
  • 市場趨勢
  • 主要的發展情形
  • 產品平台分析
  • 投資和政府的配合措施
  • GAVI及PATH計劃詳細內容
  • 合併和收購
  • 法規方案
  • PORTER'S五力
  • PEST分析

第4章 全球結合型疫苗市場-冠狀病毒(COVID-19)疫情的影響

  • 整體影響
  • COVID-19市場的影響

第5章 結合型疫苗的全球市場:各產品類型，2017年～2030年

  • 一價結合型疫苗
  • 多效價結合型疫苗

第6章 結合型疫苗的全球市場:疾病各適應症，2017年～2030年

  • 肺炎球菌
  • 流感
  • 腦膜炎
  • 傷寒症

第7章 結合型疫苗的全球市場，各病原體類型，2017年～2030年

  • 細菌性
  • 病毒性

第8章 結合型疫苗的全球市場:各患者類型，2017年～2030年

  • 兒童用
  • 成人用

第9章 結合型疫苗的全球市場:各地區，2017年～2030年

  • 北美
  • 美國
  • 加拿大
  • 南美
  • 巴西
  • 墨西哥
  • 阿根廷
  • 其他的南美地區
  • 歐洲
  • 英國
  • 德國
  • 義大利
  • 法國
  • 西班牙
  • 俄羅斯
  • 其他歐洲
  • 亞太地區
  • 中國
  • 印度
  • 日本
  • ASEAN
  • 澳洲
  • 韓國
  • 其他亞太地區
  • 中東地區
  • GCC
  • 以色列
  • 其他的中東地區
  • 非洲
  • 北非
  • 中非
  • 南非

第10章 競爭情形

  • 熱圖分析
  • 企業簡介
    • Sanofi S.A
    • Pfizer, Inc.
    • Merck & Co., Inc.
    • GlaxoSmithKline plc.
    • Bharat Biotech
    • Serum institute of India Pvt. Ltd
    • Biological E. Limited.
    • Bio-Med
    • Biological E Limited
    • CSL Limited
    • Novartis AG
    • Vaxcyte
    • GSBPL
    • Taj Pharmaceuticals Limited.
    • Bavarian Nordic

第11章 章節

  • 參考文獻
  • 調查手法的介紹
  • 關於出版社
簡介目錄
Product Code: CMI2697

Conjugate vaccine is a combination of a weak antigen with a strong antigen so as to provide active immunization against immune system having a stronger response to the weak antigen. In a conjugate vaccine, the weak antigen is covalently attached to a strong antigen and triggers stronger immunological response to the weak antigen. The weak antigen is a polysaccharide that is attached to strong protein antigen.

Conjugate vaccines target several leading causes of vaccine-preventable deaths. Advantages of conjugate vaccines include their ability to elicit immunological memory and to reduce asymptomatic carriage of the bacteria, resulting in marked herd immunity. These vaccines offer immunization from different bacterial strains. For instance, on January 24, 2022 according to the Centers for Disease Control and Prevention (CDC) April 2019 data, pneumococcal conjugate vaccine (called PCV13) protects against 13 types of pneumococcal bacteria. Whereas in 2021, US FDA (Food and Drug Administration) licensed PCV15 and PCV20 for use in adults 18 years or older. Clinical trial data showed that PCV15 and PCV20 caused the body's immune system to create antibodies, which helped fight the pneumococcal bacteria, similar to PCV13.

Market Dynamics

Increasing prevalence of pneumonia cases are expected to drive growth of the global conjugate vaccine market over the forecast period. For instance, in August 2021, National Center for Biotechnology Information, published a report on Community-Acquired Pneumonia, which reported that the estimated worldwide incidence of community-acquired pneumonia varies between 1.5 to 14 cases per 1000 person-years, and this is affected by geography, season, and population characteristics. In the U.S., the annual incidence is 24.8 cases per 10,000 adults with higher rates as age increases, whereas the mortality rate is as high as 23% for patients admitted to the intensive care unit.

Increasing initiatives taken by the governments of countries to launch new vaccines are expected to drive growth of the global conjugate vaccine market over the forecast period. For instance, in October 2021, Union Health Minister (India), Dr. Mansukh Mandaviya, launched a nationwide expansion of Pneumococcal 13-valent Conjugate Vaccine (PCV) under the Universal Immunization Programme (UIP) as a part of Azadi ka Amrit Mahotsav. Whereas, on the other hand communication and awareness packages on PVC were also made available in India.

Key features of the study:

  • This report provides an in-depth analysis of the global conjugate vaccine market and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2022 - 2030), considering 2021, as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by key players
  • It profiles key players in the global conjugate vaccine market based on following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
  • Key companies covered as a part of this study include, Sanofi S.A, Pfizer, Inc., Merck & Co., Inc., GlaxoSmithKline plc., Bharat Biotech, Serum institute of India Pvt. Ltd., Biological E. Limited, Bio-Med, Bavarian Nordic, CSL Limited, Novartis AG, Vaxcyte, GSBPL, Taj Pharmaceuticals Limited, and Bavarian Nordic
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
  • The global conjugate vaccine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the global conjugate vaccine market

Detailed Segmentation:

  • Global Conjugate Vaccine Market, By Product Type:
    • Monovalent Conjugate Vaccine
    • Multivalent Conjugate Vaccine
  • Global Conjugate Vaccine Market, By Disease Indication:
    • Pneumococcal
    • Influenza
    • Meningococcal
    • Typhoid
  • Global Conjugate Vaccine Market, By Pathogen Type:
    • Bacterial
    • Viral
  • Global Conjugate Vaccine Market, By Patients Type:
    • Pediatric
    • Adults
  • Global Conjugate Vaccine Market, By Region:
    • North America
      • By country
    • U.S.
    • Canada
    • Latin America
      • By Country
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
    • Europe
      • By Country
    • U.K.
    • Germany
    • Italy
    • Spain
    • France
    • Russia
    • Rest of Europe
    • Asia Pacific
      • By Country
    • Australia
    • India
    • China
    • Japan
    • ASEAN
    • South Korea
    • Rest of Asia Pacific
    • Middle East
      • By Country
    • GCC
    • Israel
    • Rest of Middle East
    • Africa
      • By Country/Region
    • South Africa
    • Central Africa
    • North Africa
  • Company Profiles
    • Sanofi S.A*
      • Company Highlights
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Market Strategies
    • Pfizer, Inc.
    • Merck & Co., Inc.
    • GlaxoSmithKline plc
    • Bharat Biotech.
    • Serum institute of India Pvt. Ltd.
    • Biological E. Limited
    • Bio-Med
    • Biological E Limited
    • CSL Limited
    • Novartis AG
    • Vaxcyte
    • GSBPL
    • Taj Pharmaceuticals Limited.
    • Bavarian Nordic

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
  • Market Definition and Scope
  • Executive Summary
    • Market Snapshot, By Product Type
    • Market Snapshot, By Disease Indication
    • Market Snapshot, By Pathogen Type
    • Market Snapshot, By Patient Types
    • Market Snapshot, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Market Trends
  • Key Developments
  • Product Pipeline Analysis
  • Investments and Government Initiatives
  • GAVI and PATH Program Details
  • Merger and Acquisition
  • Regulatory Scenario
  • PORTER'S Five Forces
  • PEST Analysis

4. Global Conjugate Vaccine Market- Impact of Coronavirus (Covid-19) Pandemic

  • Overall Impact
  • COVID-19 Impact on the market

5. Global Conjugate Vaccine Market, By Product Type, 2017 - 2030, (US$ Million)

  • Overview
    • Market Share Analysis, 2022 and 2030 (%)
    • Y-o-Y Growth Analysis, 2017 - 2030
    • Segment Trends
  • Monovalent Conjugate Vaccine
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Multivalent Conjugate Vaccine
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

6. Global Conjugate Vaccine Market, By Disease Indication, 2017 - 2030, (US$ Million)

  • Overview
    • Market Share Analysis, 2022 and 2030 (%)
    • Y-o-Y Growth Analysis, 2017 - 2030
    • Segment Trends
  • Pneumococcal
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Influenza
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Meningococcal
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Typhoid
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

7. Global Conjugate Vaccine Market, By Pathogen Type, 2017 - 2030, (US$ Million)

  • Overview
    • Market Share Analysis, 2022 and 2030 (%)
    • Y-o-Y Growth Analysis, 2017 - 2030
    • Segment Trends
  • Bacterial
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Viral
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

8. Global Conjugate Vaccine Market, By Patient Type,2017 - 2030, (US$ Million)

  • Overview
    • Market Share Analysis, 2022 and 2030 (%)
    • Y-o-Y Growth Analysis, 2017- 2030
    • Segment Trends
  • Paediatric
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Adult
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

9. Global Conjugate Vaccine Market, By Region, 2017 - 2030, (US$ Million)

  • Introduction
    • Market Share Analysis, By Region, 2022 and 2030 (%)
    • Y-o-Y Growth Analysis, For Regions, 2017-2030
    • Regional Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017 - 2030, (US$ Million )
    • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2017 - 2030, (US$ Million )
    • Market Size and Forecast, and Y-o-Y Growth, By Pathogen Type, 2017 - 2030, (US$ Million )
    • Market Size and Forecast, and Y-o-Y Growth, By Patient Type, 2017 - 2030, (US$ Million )
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million )
  • U.S.
  • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017 - 2030, (US$ Million )
    • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2017 - 2030, (US$ Million )
    • Market Size and Forecast, and Y-o-Y Growth, By Pathogen Type, 2017 - 2030, (US$ Million )
    • Market Size and Forecast, and Y-o-Y Growth, By Patient Type, 2017 - 2030, (US$ Million )
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million )
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017 - 2030, (US$ Million )
    • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2017 - 2030, (US$ Million )
    • Market Size and Forecast, and Y-o-Y Growth, By Pathogen Type, 2017 - 2030, (US$ Million )
    • Market Size and Forecast, and Y-o-Y Growth, By Patient Type, 2017 - 2030, (US$ Million )
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million )
  • U.K.
  • Germany
  • Italy
  • France
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017 - 2030, (US$ Million )
    • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2017 - 2030, (US$ Million )
    • Market Size and Forecast, and Y-o-Y Growth, By Pathogen Type, 2017 - 2030, (US$ Million )
    • Market Size and Forecast, and Y-o-Y Growth, By Patient Type, 2017 - 2030, (US$ Million )
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million )
  • China
  • India
  • Japan
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017 - 2030, (US$ Million )
    • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2017 - 2030, (US$ Million )
    • Market Size and Forecast, and Y-o-Y Growth, By Pathogen Type, 2017 - 2030, (US$ Million )
    • Market Size and Forecast, and Y-o-Y Growth, By Patient Type, 2017 - 2030, (US$ Million )
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million )
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017 - 2030, (US$ Million )
    • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2017 - 2030, (US$ Million )
    • Market Size and Forecast, and Y-o-Y Growth, By Pathogen Type, 2017 - 2030, (US$ Million )
    • Market Size and Forecast, and Y-o-Y Growth, By Patient Type, 2017 - 2030, (US$ Million )
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million )
  • North Africa
  • Central Africa
  • South Africa

10. Competitive Landscape

  • Heat Map Analysis
  • Company Profile
    • Sanofi S.A
  • Company Highlights
  • Product Portfolio
  • Financial Performance
  • Recent Highlights
  • Market Strategies
    • Pfizer, Inc.
    • Merck & Co., Inc.
    • GlaxoSmithKline plc.
    • Bharat Biotech
    • Serum institute of India Pvt. Ltd
    • Biological E. Limited.
    • Bio-Med
    • Biological E Limited
    • CSL Limited
    • Novartis AG
    • Vaxcyte
    • GSBPL
    • Taj Pharmaceuticals Limited.
    • Bavarian Nordic
  • Analyst Views

11. Section

  • References
  • Research Methodology
  • About Us